Infliximab-induced psoriasis during therapy for Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 610-616

  Steinwurz, Flavio ^a   Denadai, Rafael ^b   Saad Hossne, Rogério ^b   Queiroz, Maria Luiza ^a   Teixeira, Fábio Vieira ^b   Romiti, Ricardo ^c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biological therapy; Crohn's disease; Infliximab; Psoriasis; Tumor necrosis factor alpha inhibitors

Indexed keywords

ADALIMUMAB; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CLOBETASOL; INFLIXIMAB;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; DRUG WITHDRAWAL; ERYTHEMA; EVENING DOSAGE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MEDLINE; PHOTOTHERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; RELAPSE; SUNBATHING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860835842     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.12.007     Document Type: Article

References (46)

1. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508. 10.1136/gut.2008.163642.
2. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215. 10.1136/ard.2007.087288.
3. de Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
4. Wollina U., Hansel G., Koch A., Schönlebe J., Köstler E., Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
5. Rahier J.F., Buche S., Peyrin-Biroulet L., Bouhnik Y., Duclos B., Louis E., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8:1048-1055. 10.1016/j.cgh.2010.07.022.
6. Collamer A.N., Guerrero K.T., Henning J.S., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001. 10.1002/art.23835.
7. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20:100-108. 10.1080/09546630802441234.
8. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40:233-240. 10.1002/art.23835.
9. Fiorino G., Allez M., Malesci A., Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:921-927.
10. Verea M.M., Del Pozo J., Yebra-Pimentel M.T., Porta A., Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004, 38:54-57. 10.1345/aph.1C477.
11. Peramiquel L., Puig L., Dalmau J., Ricart E., Roe E., Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol 2005, 30:713-714. 10.1111/j.1365-2230.2005.01882.x.
12. Angelucci E., Cocco A., Viscido A., Vernia P., Caprilli R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm Bowel Dis 2007, 13:1059-1061. 10.1002/ibd.20137.
13. Adams D.R., Buckel T., Sceppa J.A. Infliximab associated new-onset psoriasis. J Drugs Dermatol 2006, 5:178-179.
14. Umeno J., Matsumoto T., Jo Y., Ichikawa M., Urabe K., Iida M. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2007, 13:1188-1189. 10.1002/ibd.20150.
15. Papadavid E., Gazi S., Dalamaga M., Stavrianeas N., Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol 2008, 22:380-382. 10.1111/j.1468-3083.2007.02335.x.
16. Takahashi H., Hashimoto Y., Ishida-Yamamoto A., Ashida T., Kohgo Y., Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol 2007, 34:468-472. 10.1111/j.1346-8138.2007.00312.x.
17. Passarini B., Infusino S.D., Barbieri E., Varotti E., Gionchetti P., Rizzello F., et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 2007, 215:295-300. 10.1159/000107622.
18. Cohen J.D., Bournerias I., Buffard V., Paufler A., Chevalier X., Bagot M., et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007, 34:380-385.
19. Pirard D., Arco D., Debrouckere V., Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 2006, 213:182-186. 10.1159/000095033.
20. Laga A.C., Vleugels R.A., Qureshi A.A., Velazquez E.F. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 2010, 32:568-573. 10.1097/DAD.0b013e3181cb3ff7.
21. Medkour F., Babai S., Chanteloup E., Buffard V., Delchier J.C., Le-Louet H. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol Clin Biol 2010, 34:140-141. 10.1016/j.gcb.2009.10.021.
22. Avila Alvarez A., García-Alonso L., Solar Boga A., García-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An Pediatr (Barc) 2009, 70:278-281. 10.1016/j.anpedi.2008.11.013.
23. Manni E., Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol 2009, 22:841-844.
24. Park B.C., Lim H.J., Kim B.S., Lee W.J., Kim do W., Lee S.J. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann Dermatol 2009, 21:60-62.
25. English P.L., Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J Cutan Med Surg 2009, 13:40-42. 10.2310/7750.2008.07080.
26. Costa-Romero M., Coto-Segura P., Suarez-Saavedra S., Ramos-Polo E., Santos-Juanes J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008, 14:1462-1463. 10.1002/ibd.20450.
27. Richetta A., Mattozzi C., Carlomagno V., Maiani E., Carboni V., Giancristoforo S., et al. A case of infliximab-induced psoriasis. Dermatol Online J 2008, 14:9.
28. Conklin L.S., Cohen B., Wilson L., Cuffari C., Oliva-Hemker M. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat Rev Gastroenterol Hepatol 2010, 7:174-177. 10.1038/nrgastro.2010.7.
29. Goldstein J., Levine J. Infliximab-induced psoriaform rash. Clin Gastroenterol Hepatol 2010, 8:A24. 10.1016/j.cgh.2010.04.015.
30. Pourciau C., Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol 2010, 27:539-540. 10.1111/j.1525-1470.2010.01267.x.
31. Hiremath G., Duffy L., Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011, 52:230-232. 10.1097/MPG.0b013e3181f3d9ab.
32. Tichy M., Tichy M., Kopova R., Sternbersky J., Ditrichova D. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease. J Dermatol Treat Jan 22, 2011, [Epub ahead of print]. 10.3109/09546634.2010.521811.
33. Pérez-Pérez L., Caeiro J.L., Fabeiro J.M., Allegue F., Zulaica A. Induction of pustular lesions during infliximab therapy for Crohn's disease. Acta Derm Venereol 2008, 88:292-293. 10.2340/00015555-0425.
34. Severs G.A., Lawlor T.H., Purcell S.M., Adler D.J., Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 2007, 80:231-237.
35. Wermuth J., Kind F., Steuerwald M. Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis. Clin Gastroenterol Hepatol 2009, 7:A28. 10.1016/j.cgh.2008.08.009.
36. Iborra M., Beltrán B., Bastida G., Aguas M., Nos P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2011, 5:157-161. 10.1016/j.crohns.2010.11.001.
37. Viguier M., Richette P., Bachelez H., Wendling D., Aubin F. Paradoxical cutaneous manifestations during anti-TNF-alpha therapy. Ann Dermatol Venereol 2010, 137:64-71. 10.1016/j.annder.2009.10.003.
38. Bordel-Gómez M.T., Sánchez-Estella J., Martínez-González O., Cardeñoso-Alvarez M.E. Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2009, 23:444-445. 10.1111/j.1468-3083.2008.02898.x.
39. Kerbleski J.F., Gottlieb A.B. Dermatological complications and safety of anti-TNF treatments. Gut 2009, 58:1033-1039. 10.1136/gut.2008.163683.
40. Langley R.G., Strober B.E., Gu Y., Rozzo S.J., Okun M.M. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010, 162:1349-1358. 10.1111/j.1365-2133.2010.09707.x.
41. Najarian D.J., Gottlieb A.B. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003, 48:805-821. 10.1067/mjd.2003.540.
42. Mocciaro F., Renna S., Orlando A., Cottone M. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol 2009, 104:2867-2868. 10.1038/ajg.2009.396.
43. United States Food and Drug Administration (FDA) Postmarket drug safety information for patients and providers. FDA alert 8/4/2009: Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia and Simponi) Accessed April 20, 2011, at. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm.
44. Seneschal J., Milpied B., Vergier B., Lepreux S., Schaeverbeke T., Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009, 161:1081-1088. 10.1111/j.1365-2133.2009.09329.x.
45. Basavaraj K.H., Ashok N.M., Rashmi R., Praveen T.K. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010, 49:1351-1361. 10.1111/j.1365-4632.2010.04570.x.
46. Gilliet M., Conrad C., Geiges M., Cozzio A., Thürlimann W., Burg G., et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004, 140:1490-1495.